Alcohol use disorder (AUD) is notoriously difficult to treat, with pharmacological options often underutilized or only modestly effective. But what if a medication already used for diabetes and obesity could help?

Substance use in correctional settings is a hidden crisis that significantly impacts the health and safety of both patients and staff.

In our note from the Editor in Chief, Dr. Feder underlines the hope for better outcomes for the ravages of substance use disorders and a timely message for those impacted wildfires and other disasters.

Buprenorphine is a first-line treatment for opioid use disorder, however, given buprenorphine to a patient who still has opioids in their system can precipitate severe withdrawal. Careful assessment of withdrawal can minimize the risk, but despite our best efforts, precipitated withdrawal can still occur. In this article, we review what to do for our patients experiencing buprenorphine-precipitated opioid withdrawal.

Urine drug screens are frequently ordered for patients receiving addiction treatment. However, the results of these everyday tests can have outsized consequences for patients involved in the legal system. Here, we provide an overview of how drug testing is used in the legal system and how you can be an advocate for your patient.

Nootropics are a broad class of medications encompassing many different mechanisms of action that are marketed as cognitive enhancers. Not only do most nootropics lack evidence of efficacy, but some can have dangerous side effects and addictive potential. Here, we discuss some of the most concerning nootropics being widely used today.

It’s a dilemma that will challenge the most seasoned psychopharmacologist: “My Adderall spilled down the sink.” We clarify how to respond in the post-lockdown landscape.